Patents Assigned to Synta Pharmaceuticals
  • Compounds for the treatment of proliferative disorders
    Patent number: 8399435
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: March 19, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Jun Jiang, Christopher Borella, Shoujun Chen, Keizo Koya
  • BIS[THIOHYDRAZIDE AMIDE] COMPOUNDS FOR TREATING LEUKEMIA
    Publication number: 20130035386
    Abstract: Certain bis[thio-hydrazide amide]-related compounds are found to be surprisingly effective at treating with leukemia, e.g., acute myeloid leukemia (AML). Methods of treating a subject with AML including administering bis[thio-hydrazide amide]-related compounds described herein, are disclosed.
    Type: Application
    Filed: December 6, 2010
    Publication date: February 7, 2013
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Masazumi Nagai, Jianhua Shen
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8362055
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: January 29, 2013
    Assignee: Synta Pharmaceuticals, Inc.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
  • Vinyl-aryl derivatives for inflammation and immune-related uses
    Patent number: 8349841
    Abstract: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. In some embodiments, compounds of structural formula (I): or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, are provided.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: January 8, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventor: Shoujun Chen
  • Pyrazole compounds that modulate HSP90 activity
    Patent number: 8329899
    Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: December 11, 2012
    Assignee: Synta Pharmaceuticals, Corp.
    Inventors: Weiwen Ying, Shijie Zhang, Zhenjian Du, Kevin Foley
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8329736
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: December 11, 2012
    Assignee: Synta Pharmaceuticals, Corp.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Teresa Kowalczyk Przewloka, Shijie Zhang, Kevin Foley, Zhenjian Du, Dan Zhou, Shuzhen Qin
  • Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
    Patent number: 8324219
    Abstract: This invention relates to certain biologically active chemical compounds, such as benzoimidazolyl-pyrazine derivatives of formula (I) or pharmaceutically acceptable salts thereof. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: December 4, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Junyi Zhang, Lijun Sun
  • Fused hetrocyclic compounds
    Patent number: 8318730
    Abstract: This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: November 27, 2012
    Assignee: Synta Pharmaceuticals Corporation
    Inventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Teresa Przewloka, Hao Li, Zachary Demko, Dinesh Chimmanamada
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8318790
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: November 27, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Junghyun Chae, Teresa Przewloka, Howard P. Ng, Hao Li, Zachary Demko, Dinesh U. Chimmanamada, Chi-wan Lee, Zhenjian Du, Kevin Foley, Minghu Song, Lijun Sun, Keizo Koya, Dan Zhou, Shuzhen Qin
  • Compounds for inflammation and immune-related uses
    Patent number: 8314134
    Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: November 20, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Hao Li, David James, Dinesh Chimmanamada, Christopher Borella, Lijun Sun, Yu Xie, Mats Holmqvist, Jerome Mahiou, Zhiqiang Xia
  • Compounds inclunding substituted pyridines for inflammation and immune-related uses
    Patent number: 8314130
    Abstract: The invention relates to certain compounds including substituted pyridines, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: November 20, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Junyi Zhang, Jun Jiang, Gary Bohnert, Nha Vo, Qinglin Che, Zhiqiang Xia, Lijun Sun
  • COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
    Publication number: 20120289483
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 15, 2012
    Applicant: SYNTA PHARMACEUTICALS CORPORATION
    Inventors: Lijun Sun, Christopher Borella, Hao Li, Jun Jiang, Shoujun Chen, Keizo Koya, Takayo Inoue, Zhenjian Du, Kevin Foley, Yaming Wu, Mei Zhang, Weiwen Ying
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120283272
    Abstract: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 8, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Junyi Zhang, Jun Jiang, Gary Bohnert, Nha Vo, Qinglin Che, Zhiqiang Xia, Lijun Sun
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8299107
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to the use of a substituted triazole compound of the invention, or a composition comprising such a compound in the preparation of a medicament for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: October 30, 2012
    Assignee: Synta Pharmaceuticals Corporation
    Inventors: Dinesh U. Chimmanamada, Joseph A. Burlison, Weiwen Ying, Lijun Sun, Stefan Michael Schweizer, Shijie Zhang, Zachary Demko, David James, Teresa K. Przewloka
  • COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20120245186
    Abstract: Disclosed is a method for treating a subject with cancer, comprising administering to the subject an effective amount of paclitaxel or a paclitaxel analogue and an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: October 19, 2010
    Publication date: September 27, 2012
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • Compounds for the treatment of proliferative disorders
    Patent number: 8269017
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: September 18, 2012
    Assignee: Synta Pharmaceuticals Corporation
    Inventors: Lijun Sun, Christopher Borella, Hao Li, Jun Jiang, Shoujun Chen, Keizo Koya, Takayo Inoue, Zhenjian Du, Kevin Foley, Yaming Wu, Mei Zhang, Weiwen Ying
  • COMBINATION CANCER THERAPY WITH BIS(THIOHYDRAZIDE) AMIDE COMPOUNDS
    Publication number: 20120232134
    Abstract: Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 ?mol/m2 to 315 ?mol/m2; and a bis(thiohydrazide amide) compound in an amount between about 1473 ?mol/m2 and about 1722 ?mol/m2.
    Type: Application
    Filed: September 12, 2011
    Publication date: September 13, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Thomas A. Dahl, Matthew McLeod
  • IL-12 Modulatory compounds
    Patent number: 8263764
    Abstract: The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: September 11, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Zachary Demko, Lijun Sun, Howard P. Ng
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120225883
    Abstract: The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 6, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Shoujun Chen, Zhi-Qiang Xia, Jun Jiang, Yu Xie, Junyi Zhang
  • COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION
    Publication number: 20120208203
    Abstract: The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NF?B and/or the amount of I?B. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NF?B and/or the amount of I?B is materially unaltered.
    Type: Application
    Filed: February 7, 2012
    Publication date: August 16, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Rongzhen Lu, James Barsoum, Yumiko Wada